Publicaciones en colaboración con investigadores/as de Dana–Farber Cancer Institute (8)

2024

  1. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

2022

  1. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

    Journal for immunotherapy of cancer, Vol. 10, Núm. 5

2021

  1. Type 2 immunity is maintained during cancer-associated adipose tissue wasting

    Immunotherapy Advances, Vol. 1, Núm. 1

2017

  1. Results from an integrated safety analysis of urelumab, an agonist anti-CD137 monoclonal antibody

    Clinical Cancer Research, Vol. 23, Núm. 8, pp. 1929-1936

  2. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma

    Clinical Cancer Research

2014

  1. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013

    Journal of Translational Medicine, Vol. 12, Núm. 1

2011

  1. Defining the critical hurdles in cancer immunotherapy

    Journal of Translational Medicine